Natco Pharma share news, announcements and annual reports
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Natco Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Dec 1995 on NSE
Last close ₹793.00down ₹1.55 (0.20%)BSE ₹793.35
Share price at the NSE close on 28 Oct 2026. Previous close ₹794.55.
28 Oct: open ₹785.00, high ₹802.00, low ₹779.05
52-week range of traded prices to 28 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,556 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.59
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,43,95557.8% delivered
Natco Pharma board and management
33 filed, newest first.
Jul 2026
Feb 2026
Dec 2025
Oct 2025
Sep 2025
Jul 2025
18 Jul · Management
Jun 2025
May 2025
Mar 2025
Feb 2025
27 Feb · Management
Nov 2024
Oct 2024
Sep 2024
Aug 2024
12 Aug · Management
Jul 2024
Jun 2024
Feb 2024
29 Feb · Management
14 Feb · Management
Dec 2023
28 Dec · Management
Nov 2023
Aug 2022
Mar 2022
Feb 2022
14 Feb · Management
May 2019
27 May · Management
Aug 2017
Aug 2014
May 2013
30 May · Management
Dr. Jasti Sambasiva Rao, Director of the Company resigned as a Director due to his personal preoccupations.
May 2012
9 May · Management
EXIM Bank of India has withdrawn its Nominee Shri C.P. Ravindranath and appointed Shri. T V Rao as its Nominee Director on the Board.
Jan 2007
3 Jan · Management
Dr.M.Rami Reddy, Director of our Company resigned as Director from the Board of Directors of the Company w.e.f. 31-12-2006